$INSM · INSMED Inc
Insmed filed its 10-Q for the quarter ended September 30, 2026, reporting product revenues of $524.4M, a 268% increase from $142.3M in Q3 2025. The surge was driven by BRINSUPRI, which generated $400.1M in total Q3 revenue (US: $398.1M) following its August 2025 US approval. Operating loss narrowed to $89.4M from $366.0M, and net loss per share improved to $0.46 from $1.75. The company held $1.15B in cash and marketable securities.
- Q3 product revenues hit $524.4M, up 268% YoY from $142.3M, driven by BRINSUPRI US sales of $398.1M.
- BRINSUPRI total Q3 revenue was $400.1M vs $28.1M a year ago, reflecting its first full quarter post-approval.
- Operating loss narrowed to $89.4M from $366.0M YoY; net loss improved to $100.3M ($0.46/share) from $370.0M ($1.75/share).
- Cost of product revenues as % of revenue improved to 14.9% from 20.6% YoY, indicating operating leverage.
- Cash and marketable securities totaled $1.15B at quarter-end; cash used in operations fell to $348.0M YTD from $687.4M.
Extended-hours trading shows INSM at $111.65, up 15.13% vs the regular close of $96.98, suggesting the market is rewarding the dramatic revenue ramp and sharply narrowing losses. The $21.18B market cap reflects high expectations that the BRINSUPRI launch trajectory is delivering.
Insmed's BRINSUPRI is delivering one of the strongest rare-disease launches in recent biotech history, with revenue nearly quadrupling YoY and the company approaching operating breakeven far faster than expected.
Insmed's BRINSUPRI launch in bronchiectasis — a disease with no previously approved therapy — is tracking as one of the strongest rare-disease launches in biotech. The 268% revenue growth and margin improvement signal rapid commercial execution that peers in the rare respiratory space rarely achieve this early.
Reliance on BRINSUPRI for the vast majority of revenue growth; ARIKAYCE grew only 9% YoY. The company remains unprofitable with a $5.9B accumulated deficit and $544.9M in long-term debt. Contingent consideration liability of $178.1M adds balance-sheet complexity.